Jeff Yass’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-60,989
| Closed | -$63.3K | – | 10776 |
|
|
2018
Q3 | $79K | Buy |
60,989
+18,954
| +45% | +$29.4K | ﹤0.01% | 8691 |
|
|
2018
Q2 | $57K | Buy |
42,035
+15,040
| +56% | +$23K | ﹤0.01% | 9240 |
|
|
2018
Q1 | $39K | Sell |
26,995
-136,310
| -83% | -$285K | ﹤0.01% | 9026 |
|
|
2017
Q4 | $368K | Buy |
163,305
+91,493
| +127% | +$232K | ﹤0.01% | 7215 |
|
|
2017
Q3 | $244K | Sell |
71,812
-18,200
| -20% | -$61.2K | ﹤0.01% | 7722 |
|
|
2017
Q2 | $320K | Buy |
+90,012
| New | +$297K | ﹤0.01% | 7476 |
|
|
2017
Q1 | – | Sell |
-34,373
| Closed | -$134K | – | 10916 |
|
|
2016
Q4 | $158K | Buy |
34,373
+22,187
| +182% | +$91.5K | ﹤0.01% | 8820 |
|
|
2016
Q3 | $52K | Buy |
+12,186
| New | +$39.4K | ﹤0.01% | 8115 |
|
|
2015
Q4 | – | Sell |
-23,524
| Closed | -$91K | – | 10643 |
|
|
2015
Q3 | $91K | Buy |
23,524
+7,431
| +46% | +$34.1K | ﹤0.01% | 9185 |
|
|
2015
Q2 | $74K | Sell |
16,093
-16,657
| -51% | -$160K | ﹤0.01% | 9772 |
|
|
2015
Q1 | $221K | Buy |
+32,750
| New | +$162K | ﹤0.01% | 8493 |
|
Jeff Yass's AST Position: Q4 2018 in Review
Jeff Yass sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2018, closing a stake of 60,989 shares — an estimated $63.3K sold.
Jeff Yass first reported a position in AST in Q1 2015 and held it in 11 quarters. The position peaked at $368K in Q4 2017. 46 funds tracked by Wall St. Rank hold AST as of Q4 2018.
- Jeff Yass reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2018 after selling out during the quarter.
- Jeff Yass sold 60,989 Asterias Biotherapeutics Inc. Series A shares in Q4 2018, an estimated $63.3K.
- Jeff Yass first reported a position in Asterias Biotherapeutics Inc. Series A in Q1 2015 and held it in 11 quarters.
- Jeff Yass's Asterias Biotherapeutics Inc. Series A position peaked at $368K in Q4 2017.
- 46 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2018.
Based on Susquehanna International Group's 13F filing for Q4 2018, filed 14 Feb 2019.